title: GRAPPA 2013 basic/translational/clinical science update: comorbidity monitoring.
abstract: It is now well established that psoriatic disease is associated with increased cardiovascular (CV) risk. Screening guidelines and expert recommendations for CV risk factors have been published, but these are primarily directed to specific specialists (e.g., cardiologists or diabetologists) and may not be well known in common practice. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and other organizations are interested in adapting current comorbidity screening guidelines for use by dermatologists and rheumatologists. The resulting checklists and algorithms will need to be evaluated for practicability and performance.
authors.affiliation: From the Department of Dermatology, Geneva University Hospital, Geneva, Switzerland.W-H. Boehncke, MD. wolf-henning.boehncke@hcuge.ch.
authors.forename: Wolf-Henning
authors.initials: WH
authors.lastname: Boehncke
mesh_terms: D015535:Arthritis, Psoriatic / Q000150:complications*; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000209:etiology*; D006801:Humans; D011565:Psoriasis / Q000150:complications*; D012307:Risk Factors
keywords: CARDIOVASCULAR RISK; COMORBIDITIES; MORTALITY; MYOCARDIAL INFARCTION; PSORIASIS; SCREENING